Clinical Trial Update: Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This document reports the completion and posting of results for a Phase 2 clinical trial evaluating dinaciclib in patients with relapsed or refractory multiple …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Dinaciclib (dinaciclib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2013-02-25